MXPA04001191A - Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina. - Google Patents

Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina.

Info

Publication number
MXPA04001191A
MXPA04001191A MXPA04001191A MXPA04001191A MXPA04001191A MX PA04001191 A MXPA04001191 A MX PA04001191A MX PA04001191 A MXPA04001191 A MX PA04001191A MX PA04001191 A MXPA04001191 A MX PA04001191A MX PA04001191 A MXPA04001191 A MX PA04001191A
Authority
MX
Mexico
Prior art keywords
phenyl
pyrrolo
pyrimidin
amine
ylmethyl
Prior art date
Application number
MXPA04001191A
Other languages
English (en)
Spanish (es)
Inventor
Caravatti Giorgio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA04001191A publication Critical patent/MXPA04001191A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA04001191A 2001-08-07 2002-08-06 Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina. MXPA04001191A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119249.1A GB0119249D0 (en) 2001-08-07 2001-08-07 Organic compounds
PCT/EP2002/008780 WO2003013541A1 (en) 2001-08-07 2002-08-06 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MXPA04001191A true MXPA04001191A (es) 2005-02-17

Family

ID=9919959

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001191A MXPA04001191A (es) 2001-08-07 2002-08-06 Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina.

Country Status (31)

Country Link
US (2) US7244729B2 (enExample)
EP (1) EP1416935B8 (enExample)
JP (1) JP4147184B2 (enExample)
KR (1) KR100597505B1 (enExample)
CN (2) CN101560214B (enExample)
AR (1) AR036213A1 (enExample)
AT (1) ATE388713T1 (enExample)
AU (1) AU2002324029B2 (enExample)
BR (1) BR0211801A (enExample)
CA (1) CA2453881C (enExample)
CY (1) CY1108129T1 (enExample)
DE (1) DE60225563T2 (enExample)
DK (1) DK1416935T3 (enExample)
EC (1) ECSP034444A (enExample)
ES (1) ES2302830T3 (enExample)
GB (1) GB0119249D0 (enExample)
HU (1) HUP0401083A3 (enExample)
IL (2) IL159832A0 (enExample)
MX (1) MXPA04001191A (enExample)
MY (1) MY140398A (enExample)
NO (1) NO328791B1 (enExample)
NZ (1) NZ530824A (enExample)
PE (1) PE20030349A1 (enExample)
PL (1) PL365783A1 (enExample)
PT (1) PT1416935E (enExample)
RU (1) RU2318826C2 (enExample)
SG (1) SG156521A1 (enExample)
SI (1) SI1416935T1 (enExample)
TW (1) TWI324159B (enExample)
WO (1) WO2003013541A1 (enExample)
ZA (1) ZA200400271B (enExample)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK17342002A3 (sk) * 2000-06-26 2004-06-08 Pfizer Products Inc. Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu
AU2002340139A1 (en) * 2001-10-09 2003-04-22 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
BR0311173A (pt) 2002-05-16 2005-03-15 Novartis Ag Uso de agentes de ligação do receptor de edg em câncer
NZ601544A (en) 2003-08-27 2013-11-29 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
MXPA06005882A (es) * 2003-11-25 2006-06-27 Pfizer Prod Inc Metodo de tratamiento de la aterosclerosis.
AR047470A1 (es) * 2004-01-29 2006-01-18 Novartis Ag Derivados de pirrolo-pirimidina utiles para el tratamiento de enfermedades proliferativas,composiciones farmaceuticas que los contienen,y procesos para su preparacion
GB0403606D0 (en) 2004-02-18 2004-03-24 Novartis Ag Organic compounds
US20080269238A1 (en) * 2004-04-01 2008-10-30 Takeda Pharmaceutical Company Limited Thiazolopyrimidine Derivative
ME02125B (me) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
EP1752457B1 (en) 2004-06-02 2014-03-19 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
BRPI0513982A (pt) * 2004-07-30 2007-11-27 Methylgene Inc inibidores de sinalização de receptor de vegf e receptor de hgf
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
DK1827437T3 (da) 2004-12-15 2012-02-13 Sigma Tau Ind Farmaceuti Kombinationer af terapeutiske midler til cancerbehandling
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US20080227980A1 (en) * 2005-08-05 2008-09-18 Novartis Ag Preparation of a 7H-Pyrrolo [2,3-D] Pyrimidine Derivative
EP2275103B1 (en) 2005-11-21 2014-04-23 Novartis AG mTOR inhibitors in the treatment of endocrine tumors
KR20080095859A (ko) * 2006-01-23 2008-10-29 노파르티스 아게 고체 형태의 피롤로피리미딘 유도체 및 항종양제로서의그의 용도
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
AU2007234379A1 (en) * 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
AU2007234382B2 (en) * 2006-04-05 2011-06-09 Novartis Ag Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
CN102671196B (zh) 2006-04-05 2014-12-03 诺华股份有限公司 用于治疗癌症的治疗剂的组合
NZ572299A (en) 2006-05-09 2010-07-30 Novartis Ag Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
MY146474A (en) * 2006-11-06 2012-08-15 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP2120900A2 (en) 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
US7981903B2 (en) * 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
ES2524259T3 (es) 2008-03-24 2014-12-04 Novartis Ag Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
PL2260020T3 (pl) 2008-03-26 2015-01-30 Novartis Ag Hydroksamianowe inhibitory deacetylaz B
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010149755A1 (en) 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
WO2011013656A1 (ja) * 2009-07-28 2011-02-03 第一三共株式会社 ピロロ［２，３－ｄ］ピリミジン誘導体
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
US9085560B2 (en) 2009-08-17 2015-07-21 Intellikine, Inc. Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
MX2012002420A (es) 2009-08-26 2012-06-27 Novartis Ag Compuestos de heteroarilo tetra-sustituidos y su uso como moduladores de mdm2 y/o mdm4.
NZ599565A (en) 2009-11-04 2013-05-31 Novartis Ag Heterocyclic sulfonamide derivatives useful as mek inhibitors
CA2781669A1 (en) 2009-11-23 2011-05-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EA201200823A1 (ru) 2009-12-08 2013-02-28 Новартис Аг Гетероциклические производные сульфонамидов
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
BR112013004673A8 (pt) 2010-08-31 2018-01-02 Genentech Inc biomarcadores e métodos de tratamento.
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
MX2013007336A (es) 2010-12-21 2013-08-01 Novartis Ag Compuestos de bi-heteroarilo como inhibidores de vps34.
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
MX2013014398A (es) 2011-06-09 2014-03-21 Novartis Ag Derivados de sulfonamida heterociclicos.
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
EP2723740A1 (en) 2011-06-27 2014-04-30 Novartis AG Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
KR20140058543A (ko) * 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
EP2758043A4 (en) 2011-08-17 2016-02-24 Dennis M Brown COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY APPLIED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
CA2859764C (en) 2011-12-22 2019-12-31 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
MX2014007729A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
US9126979B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
EA201491265A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
EA201491259A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
MX2014007731A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
AU2013274101B2 (en) 2012-06-15 2017-09-07 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
WO2014025395A1 (en) 2012-08-06 2014-02-13 Duke University Compounds and methods for targeting hsp90
CN104837841A (zh) 2012-09-26 2015-08-12 拜耳制药股份公司 用于治疗过度增殖性疾病的取代的吲唑-吡咯并嘧啶
US20150218173A1 (en) 2012-09-26 2015-08-06 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
CN102936251A (zh) * 2012-11-05 2013-02-20 上海毕得医药科技有限公司 一种吡咯并[2,3-d]嘧啶衍生物的制备方法
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
MX2015010791A (es) 2013-02-22 2015-11-26 Hoffmann La Roche Metodos para tratar el cancer y prevenir la resistencia a farmacos.
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
SG10201912985RA (en) 2013-07-12 2020-02-27 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
RU2675105C9 (ru) 2013-09-22 2019-01-09 Саншайн Лейк Фарма Ко., Лтд. Замещенные аминопиримидиновые соединения и способы их использования
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2015148714A1 (en) 2014-03-25 2015-10-01 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
MX2016012574A (es) 2014-03-28 2017-09-26 Calitor Sciences Llc Compuestos heteroarilo sustituidos y metodos de uso.
US10426753B2 (en) 2014-04-03 2019-10-01 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
CN109952306A (zh) * 2016-04-19 2019-06-28 加利福尼亚大学董事会 ErbB抑制剂及其用途
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
US11602534B2 (en) 2017-12-21 2023-03-14 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Pyrimidine derivative kinase inhibitors
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP3826988A4 (en) 2018-07-24 2023-03-22 Hygia Pharmaceuticals, LLC COMPOUNDS, DERIVATIVES AND ANALOGUES FOR CANCER
TW202039481A (zh) 2018-12-21 2020-11-01 美商西建公司 Ripk2之噻吩并吡啶抑制劑
EP3914698B1 (en) 2019-01-23 2024-12-11 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
CN115768890A (zh) 2020-04-15 2023-03-07 加州理工学院 通过分子和物理启动对t细胞免疫疗法的热控制
WO2022029220A1 (en) 2020-08-05 2022-02-10 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
US11814388B1 (en) 2020-08-28 2023-11-14 Ferris State University Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers
US11999964B2 (en) 2020-08-28 2024-06-04 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
GB2617409B (en) 2022-04-27 2024-06-26 Cancertain Ltd Method for predicting responsiveness to therapy
CN119816589A (zh) 2022-08-02 2025-04-11 国立大学法人北海道大学 使用细胞器复合体改善细胞疗法的方法
WO2024091370A1 (en) * 2022-10-26 2024-05-02 Acerand Therapeutics (Usa) Limited 5,6-fused bicyclic heteroaromatic compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5877178A (en) * 1991-04-08 1999-03-02 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
ATE159257T1 (de) * 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
CA2224435C (en) * 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
JPH09218320A (ja) * 1996-02-14 1997-08-19 Fujitsu Ltd 光海底中継器
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
JP2000516611A (ja) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体
US6180636B1 (en) * 1996-08-23 2001-01-30 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
AU7210398A (en) 1997-03-27 1998-10-22 Novartis Ag Intermediate products and method for the production of pyrimidine derivatives
EP1087970B1 (en) 1998-06-19 2004-04-28 Pfizer Products Inc. PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
IL148903A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Certain alkylene diamine-substituted heterocycles
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
EP1244668B1 (en) 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
EA200200688A1 (ru) 2000-01-18 2003-02-27 Пфайзер Продактс Инк. Антагонисты фактора, высвобождающего кортикотропин
MX242553B (es) 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.

Also Published As

Publication number Publication date
WO2003013541A8 (en) 2004-02-26
SI1416935T1 (sl) 2008-08-31
EP1416935B1 (en) 2008-03-12
CA2453881C (en) 2010-09-28
MY140398A (en) 2009-12-31
ATE388713T1 (de) 2008-03-15
BR0211801A (pt) 2004-08-31
DK1416935T3 (da) 2008-07-07
CY1108129T1 (el) 2014-02-12
SG156521A1 (en) 2009-11-26
PL365783A1 (en) 2005-01-10
WO2003013541A1 (en) 2003-02-20
KR100597505B1 (ko) 2006-07-10
CN1538847A (zh) 2004-10-20
ECSP034444A (es) 2004-08-27
TWI324159B (en) 2010-05-01
HK1065483A1 (en) 2005-02-25
HUP0401083A2 (hu) 2004-09-28
US20040242600A1 (en) 2004-12-02
RU2318826C2 (ru) 2008-03-10
CA2453881A1 (en) 2003-02-20
US7390805B2 (en) 2008-06-24
US7244729B2 (en) 2007-07-17
CN101560214A (zh) 2009-10-21
DE60225563D1 (de) 2008-04-24
DE60225563T2 (de) 2009-03-26
IL159832A0 (en) 2004-06-20
IL159832A (en) 2012-09-24
GB0119249D0 (en) 2001-10-03
US20070161632A1 (en) 2007-07-12
PE20030349A1 (es) 2003-05-29
NO20040540L (no) 2004-02-05
KR20040023730A (ko) 2004-03-18
EP1416935B8 (en) 2008-08-27
NO328791B1 (no) 2010-05-18
RU2004106783A (ru) 2005-07-27
PT1416935E (pt) 2008-06-18
EP1416935A1 (en) 2004-05-12
AR036213A1 (es) 2004-08-18
ES2302830T3 (es) 2008-08-01
AU2002324029B2 (en) 2005-01-27
HUP0401083A3 (en) 2007-12-28
CN101560214B (zh) 2011-05-25
ZA200400271B (en) 2004-11-01
NZ530824A (en) 2005-08-26
JP2005501077A (ja) 2005-01-13
JP4147184B2 (ja) 2008-09-10

Similar Documents

Publication Publication Date Title
MXPA04001191A (es) Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina.
AU2002324029A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
TWI704151B (zh) Ｅｒｋ抑制劑
CN110621675B (zh) 用于治疗增殖性疾病的三环化合物
JP2011530574A (ja) ２−アルキル−６−シクロアミノ−３−（ピリジン−４−イル）イミダゾ［１，２−ｉｂ］ピリダジン誘導体、この調製およびこの治療応用
JP2012131795A (ja) 増殖性疾患の処置に有用なピロロピリミジン誘導体
CA2805015A1 (en) Bicyclic pyrimidines
US7323469B2 (en) 7H-pyrrolo[2,3-d]pyrimidine derivatives
HK1065483B (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives

Legal Events

Date Code Title Description
FG Grant or registration